Concepedia

Tereza Lanitis

TL

15

Publications

492

Citations

13

H-Index

2012

Active since

Affiliations

EVRAZ (United Kingdom)(Current)

Pfizer (United States)

Ithaka Harbors

Bristol-Myers Squibb (United States)

Regeneron (United States)

Tereza Lanitis is an author at EVRAZ (United Kingdom) specializing in medicine, public health, and health policy.

ORCID

Top concepts

Publications per year

2012–2020

15

Publications

15

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

Paul Dorian, Thitima Kongnakorn, Hemant Phatak et al. · European Heart Journal · 2014 · 94 citations · Full text

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Gregory Y.H. Lip, Thitima Kongnakorn, Hemant Phatak et al. · Clinical Therapeutics · 2014 · 83 citations

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

Tereza Lanitis, François-Emery Cotté, Anne-Françoise Gaudin et al. · Journal of Medical Economics · 2014 · 70 citations · Full text

Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the United States in 2020

Andrew A. Moshfeghi, Tereza Lanitis, Georg Kropat et al. · Ophthalmic surgery, lasers & imaging retina · 2020 · 33 citations

Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation

Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson et al. · Thrombosis Research · 2014 · 30 citations · Full text

Rows per page

1–5 of 15